medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

A simplified SARS-CoV-2 pseudovirus neutralization assay
Gaetano Donofrioa*, Valentina Franceschia, Francesca Macchia, Luca Russoa, Anna Roccie,
Valentina Marchicab,d, Federica Costab,d, Nicola Giulianib, Carlo Ferrarib,c, Gabriele Missaleb,c.

a

Department of Medical-Veterinary Science, University of Parma, 43126 Parma, Italy;
Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy; cLaboratory
of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Azienda OspedalieroUniversitaria di Parma, Parma, Italy; dUnit of Hematology, Azienda OspedalieroUniversitaria di Parma, Parma, Italy. eUnit of Angiology and Internal Medicine, Azienda
Ospedaliero-Universitaria di Parma, Parma, Italy.
b

*Corresponding author:
Gaetano Donofrio D.V.M., Ph.D.
Department of Medical-Veterinary Science, University of Parma, 43126 Parma, Italy
Phone: +390521032677
E-mail: gaetano.donofrio@unipr.it

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

2
31

Abstract

32

COVID-19 is an ongoing pandemic caused by the highly infectious coronavirus SARS-CoV-2

33

that is engaging worldwide scientific research to find a timely and effective eradication strategy.

34

Great efforts have been put into anti-COVID-19 vaccine generation in an effort to protect the

35

world population and block SARS-CoV-2 spread. To validate the protective efficacy of the

36

vaccination campaign and effectively control the pandemy, it is necessary to quantify the

37

neutralizing antibodies induction by vaccination, since they have been established to be a

38

correlate of protection. In this work a SARS-CoV-2 pseudovirus neutralization assay, based on

39

a replication incompetent lentivirus expressing an adapted form of CoV-2 S protein and an

40

ACE2/TMPRSS2 stably expressing cell line, have been minimized in term of protocol steps

41

without loss of accuracy. The goal of the present simplified neutralization system is to improve

42

SARS-CoV-2 vaccination campaign by means of an easy and accessible approach to be

43

performed in any medical laboratory, maintaining the sensitivity and quantitative reliability of

44

classical serum neutralization assays. Further this assay can be easily adapted to different

45

coronaviruses variants by simply modifying the pseudotyping vector.

46
47

Keywords: SARS-CoV-2; COVID-19; neutralizing antibody; pseudovirus; neutralization

48

assay.

49
50

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

3
51

Introduction

52

Coronaviruses, belonging to the family Coronaviridae in the order Nidovirales, are positive-

53

strand RNA viruses with a genome length comprised between 26 and 32 Kbp. Several

54

mammalian and avian species can be infected by coronavirus and most of the time causing

55

respiratory and/or intestinal disease [1]. Human coronaviruses (HCoVs), such as HCoV-229E,

56

HCoV-OC43, HCoV-NL63, and HKU1, have long been recognized as major causes of the

57

common cold and are endemic in the human population. Two recent HCoVs, severe acute

58

respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome

59

coronavirus (MERS-CoV), emerged in 2002 and 2012, respectively, causing life-threatening

60

disease in humans. A previously unknown coronavirus, named SARS-CoV-2 (CoV-2), was

61

discovered in December 2019 in Wuhan, China, responsible for a pandemic infection, known

62

as coronavirus disease 19 (COVID-19) and causing a large number of deaths people worldwide

63

[1]. Despite a huge research effort has been made, COVID-19 remains a complex disease

64

showing pathogenetic mechanisms and clinical heterogeneous features difficult to understand.

65

A variety of approaches have been employed to develop prophylactic and therapeutic measures,

66

including whole inactivated vaccines, subunit vaccines, RNA-based vaccines, viral vectored

67

vaccines [2,3], monoclonal neutralizing antibodies and fusion inhibitors, most of which were

68

designed to target the CoV-2 Spike glycoprotein (S) [4,5]. CoV-2 S, forming homotrimers

69

structures on viral surface, mediates virus entry to the host cell. S mature structure is formed by

70

S1 and S2 functional subunits: S1 interacts with the Angiotensin Converting Enzyme 2 (ACE2)

71

cellular receptor, while S2 mediates the viral envelope fusion with the host cell membrane [6-

72

8]. During S1-ACE2 interaction, the host cell surface Transmembrane Serine Protease 2

73

(TMPRSS2), located next to ACE2 receptor, cleaves the S2 subunit at the S2’ amino terminal

74

portion (815↓816aa; SKR↓SFI), inducing the fusion peptide hydrophobic domains exposure

75

and the subsequent viral envelope fusion with the host cell membrane [6-8]. Due to its high

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

4
76

infectivity and pathogenicity, CoV-2 needs to be handled in biosafety level 3 (BSL-3) specific

77

facilities (https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html) [9],

78

which limits the development of anti-viral measures as well as basic and applied studies on the

79

interaction between host cells and CoV2 and viral attachment and entry mediated by the S

80

protein. To avoid dealing with infectious CoV2, several safe, biosafety level 2 (BSL2)

81

pseudovirus-based systems have been developed mainly based on vescicular stomatitis virus

82

(VSV) [10] or retrovirus (RV) [11,12] vector pseudotyped with CoV-2 S. Although both of

83

them have been shown to be sensitive and reliable, they suffer to be farraginous, time

84

consuming and expensive in procedural terms. In the present work, a 4 steps simplified

85

procedure of CoV-2 pseudovirus neutralization assay was established.

86
87

Material and Methods

88

Plasmids.

89

ACE2-IRES-TMPRSS2-IRES-Puromycin tricistronic ORF was chemically synthetized and

90

integrated into a lentiviral transfer vector to get pEF1α-ACE2/TMPRRS2/Puro (Supplementary

91

Figure 1 for details and full sequence). Similarly, S-ΔRS-HA ORF (Supplementary Figure 2)

92

and biscistronic turboGFP-IRES-Luc2 ORF were chemically synthetized and integrated into a

93

lentiviral transfer vector to get pLV-CMV-(S-ΔRS-HA)-IRES-Puro-WPRE (Supplementary

94

Figure 3) and pLV-EF1α-(turboGFP-IRES-Luc2)-WPRE respectively. p8.74 packaging,

95

pREV, pMD2 pseudotyping and pEGFP-C1 vectors were obtained from Addgene

96

(https://www.addgene.org/).

97
98

Cells.

99

Human Embryo Kidney (HEK) 293T (ATCC: CRL-11268) cells were cultured in Eagle’s

100

Minimal Essential Medium (EMEM, Gibco; Thermo Fisher Scientific, Carlsbad, CA, USA)

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

5
101

containing 1mM of Sodium Pyruvate (Gibco), 2 mM of L-glutamine (Gibco), 100 IU/mL of

102

penicillin (Gibco), 100μg/mL of streptomycin (Sigma-Aldrich, Milano, Italy), and 0.25μg/mL

103

of amphotericin B (Gibco); called complete EMEM] supplemented with 10% Fetal Bovine

104

Serum (FBS, Gibco), and were incubated at 37֯°C and 5% CO2 in a humidified incubator.

105

Stably transfected HEK/S-ΔRS-HA/Puro (HEK/S) and HEK/ACE2/TMPRRS2/Puro cells were

106

obtained transfecting cells with pLV-CMV-(S-ΔRS-HA)-IRES-Puro-WPRE or pEF1α-

107

ACE2/TMPRRS2/Puro vectors, respectively. Briefly, sub-confluent HEK 293T cells were

108

detached from a T75cm2 flask, counted and electroporated with 20 µg of pLV-CMV-(S-ΔRS-

109

HA)-IRES-Puro-WPRE or pEF1α-ACE2/TMPRRS2/Puro vectors in 600 µL of DMEM high

110

glucose (Euroclone) without serum at 186V, 1500µF in Gene Pulser XCell (Biorad, Milano,

111

Italy).

112

Electroporated cells were then transferred to new 25 cm2 flasks and fed with complete EMEM

113

with 10% FBS. Twenty-four hours after the transfection, the medium was changed with fresh

114

complete EMEM with 10% FBS complemented with 2 µg/ml of puromycin (Millipore Merck

115

Life Science, Milano, Italy). Cells were kept in culture until resistant colonies appeared. Cells

116

were split for more than 40 passages and tested for S or ACE2 expression.

117
118

Transient Transfection and syncytia formation.

119

HEK 293T cells were transiently co-transfected with pLV-CMV-(S-ΔRS-HA)-IRES-Puro-

120

WPRE, pEF1α-ACE2/TMPRRS2/Puro and pEGFP-C1 (Clontech) vectors, with same molar

121

ration (1:1:1), using polyethylenimine (PEI) transfection reagent (Polysciences, Inc.

122

Warrington, Pennsylvania, USA). Briefly, cells were seeded at 5×105cells/well in 6-well plates

123

and incubated overnight at 37 °C/5% CO2. Cells were then incubated for 6 hours with a

124

transfection mix (1 ml) containing 3μg of plasmids DNA and PEI (ratio 1:2.5 DNA-PEI) in

125

complete DMEM (Dulbecco's Modified Essential Medium (DMEM) high glucose (Euroclone)

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

6
126

completed with 50 μg/ml of Gentamicine (Merk)) without serum. After incubation, the

127

transfection mix was replaced by fresh complete EMEM and incubated for 24 hours at 37°C,

128

5% CO2. HEK/ACE2/TMPRRS2/Puro cells were transiently co-transfected with pLV-CMV-

129

(S-ΔRS-HA)-IRES-Puro-WPRE

130

HEK/ACE2/TMPRRS2/Puro cells were also co-cultivated (1:2 ratio) with HEK 293T cells

131

transiently transfected with pLV-CMV-(S-ΔRS-HA)-IRES-Puro-WPRE and pEGFP-C1.

132

Twenty-four hours post co-cultivation, syncytia were observed by inverted fluorescence

133

microscope (Zeiss-Axiovert-S100) and pictures were acquired by digital camera (Zeiss-

134

Axiocam-MRC). HEK/S-ΔRS-HA/Puro and HEK/ACE2/TMPRRS2/Puro cells were also co-

135

cultivated as before to generate syncytia.

and

pEGFP-C1

as

before.

Alternatively,

136
137

Western Immunoblotting

138

Protein cell extracts were obtained from pLV-CMV-(S-ΔRS-HA)-IRES-Puro-WPRE, and

139

pEGFP-C1 transfected HEK293T cells by adding 100μL of cell extraction buffer (50 mM Tris-

140

HCl,150 mM NaCl, and 1% NP-40; pH 8). After BCA total protein quantification (Pierce™

141

BCA Protein Assay kit, Thermo Fisher Scientific), cell extracts containing various amount of

142

total protein were electrophoresed through 10% SDS-PAGE. Proteins were then transferred to

143

a nylon membrane by electroblotting, and the membrane was incubated with mouse monoclonal

144

antibody anti-HA tag (G036, Abm Inc., Vancouver, Canada) diluted 1:10,000. After washing,

145

the membrane was incubated with a rabbit anti-mouse IgG secondary antibody labelled with

146

horseradish peroxidase, diluted 1:15,000 (A9044, Sigma-Aldrich) and visualized by enhanced

147

chemiluminescence (Clarity Max Western ECL substrate, Bio-Rad, Hercules, California,

148

USA).

149
150

Hematoxylin and Hematoxylin and Eosin staining.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

7
151

Flasks of cells containing syncytia were fixed with 4% of paraformaldehyde in PBS and

152

stained with Hematoxylin and Eosin standard method.

153
154

Pseudovirions reconstitution.

155

For reconstituting CoV-2 S pseudovirus, HEK 293T cells were transfected, in T175 cm2 flasks,

156

with 25 μg of pLV-EF1α-(turboGFP-Luc2)-WPRE transfer vector, 15 μg of p8.74 packaging

157

vector, 13 μg of pLV-CMV-(S-ΔRS-HA)-IRES-Puro-WPRE pseudotyping vector (although

158

this is a transfer vector, it can work as a pseudotyping vector too) and 5μg of pREV (58 μg of

159

total DNA), were diluted in 3 mL of complete DMEM (Euroclone) without serum and 145 μL

160

of PEI (Polysciences, Inc.) (1 mg/mL in PBS) (ratio 1:2.5 DNA-PEI). After at least 15 minuts

161

incubation at room temperature, 4x volumes of complete DMEM without serum were added

162

and the transfection solution and transferred to the cell monolayer. After 6 hours of incubation

163

at 37°C/5% CO2, in a humidified incubator, the transfection mixture was replaced with 25 mL

164

of fresh complete EMEM supplemented with 10% FBS and incubated for 48 hours at 37 °C/5%

165

CO2. The flask was then frozen-thawed at −80°C, Transfected Cells Supernatant (TCS)

166

containing S Pseudovirus was clarified via centrifugation at 3,500 rpm for 5 minutes at 4°C,

167

filtered through a 0.45 μm filter (Millipore), aliquoted, tittered by limited dilution and stored at

168

-80 °C.

169

ACE2/TMPRSS2 pseudovirus was prepared as described above by simply substituting pLV-

170

CMV-(S-ΔRS-HA)-IRES-Puro-WPRE with pEF1α-ACE2/TMPRRS2/Puro, again, although

171

this is a transfer vector, it can work as a pseudotyping vector too.

172
173

Serum samples.

174

Sera were collaboratively provided by the Unit of Infectious Diseases and Hepatology,

175

University Hospital of Parma. The study was approved by the local ethical committee (Comitato

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

8
176

Etico Area Vasta Emilia Nord (AVEN), Italy). All participants gave written informed consent

177

to participate in the study.

178
179

Seroneutralization assay.

180

25µL of complete EMEM with 10% of FBS were added to each well of a 96 wells opaque wall,

181

clear flat bottom white microplate (Greiner bio one) and 25 µL of each serum were added to

182

the first line of wells (Supplementary Figure 5). 25µL of S pseudovirus preparation (described

183

in Pseudovirions reconstitution section above) diluted in complete EMEM with 10% of FBS

184

(corresponding to ~104 Relative Luciferase Units (RLUs); ~3-5µL of the initial preparation)

185

were added to each well and left to incubate at room temperature for 1.5 hour. Final volume for

186

each well went up to 50µL, therefore the sera dilution was doubled, 1:4-1:8-1:16-1:32-1:64-

187

1:128-1:256-1:512. Next, 50µL of complete EMEM with 10% FBS, containing 104

188

HEK/ACE2/TMPRRS2/Puro cells wear added to each well and left for 60 hours at 37 °C/5%

189

CO2.

190

Plates were read by adding 25µL of complete EMEM containing Luciferine to each well just

191

before the reading of the microplate to the Luminometer (Victor, Perkin Elmer). Since the plate

192

has a transparent bottom, a dark film layer should be applied for reading. A negative control

193

was established without serum, which was substituted with complete medium. The RLUs were

194

compared and normalized to those derived from wells where pseudovirus was added in the

195

absence of sera (100%). Neutralization Titer 50 (NT50) was expressed as the maximal dilution

196

of the sera where the reduction of the signal is ≥50%. Note of worthy, the titer has to be

197

multiplied per 40 because the initial volume of the sera tested is 0,025mL and it has to be

198

normalized to 1mL.

199
200
201
202

Results and discussion
Generation of a sensitive target cell line simultaneously expressing ACE2 and TMPRRS2.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

9
203

Since ACE2 and TMPRSS2 are the main restriction factors for SARS-CoV-2 (CoV-2)

204

attachment and penetration into the host cells [7], a cell line simultaneously expressing ACE2

205

and TMPRSS2 was generated. For this purpose, a tricistronic expression cassette was

206

constructed. Human ACE2 ORF (GeneBank accession number: NM_021804.3), provided of a

207

strong Kozak’s sequence to the 5’ end, human TMPRSS2 ORF (GeneBank accession number:

208

NM_001135099.1) and the Puromycin drug resistance gene ORF were in-tandem positioned

209

and linked by two Internal Ribosomal Entry Sites (IRES) (ACE2-IRES-TMPRSS2-IRES-

210

Puromycin). This large tricistronic ORF was chemically synthetized and sub-cloned

211

downstream to the human Elongation Factor 1 alpha promoter (EF1α), upstream to the SV40

212

polyA signal/site in a pUC plasmid backbone. Thus, pEF1α-ACE2/TMPRRS2/Puro was

213

generated (Supplementary Figure 1). pEF1α-ACE2/TMPRRS2/Puro, was electroporated in

214

HEK293T cells and stably transfected cells were obtained by selection with puromycin. Since

215

puromycin drug resistance gene ORF is the last to be translated from the mRNA transcribed

216

from pEF1α-ACE2/TMPRRS2/Puro, the selection of puromycin selected resistant cells

217

(HEK/ACE2/TMPRRS2/Puro) indeed guaranteed the expression of ACE2 and TMPRSS2.

218

HEK/ACE2/TMPRRS2/Puro cells were kept, so far, for over thirty passages without loss of

219

functionality/expression. Noteworthy, HEK/ACE2/TMPRRS2/Puro cells do not need to be

220

constantly maintained in culture, under puromycin selection: a large batch of them can be

221

grown, aliquoted at a suitable concentration, stored at -80 C° or in liquid nitrogen and

222

successively used, when needed, by simply thawing an aliquot of them, without any loss of

223

functionality.

224
225

Expression of SARS-CoV-2 Spike glycoprotein in mammalian cells.

226

CoV-2 S is a key factor for SARS-CoV-2 target cell infection [6-8]. Antibodies from COVID-

227

19 convalescent patient sera can block in vitro and in vivo CoV-2 infectivity, thus being

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

10
228

exploitable for CoV-2 infection diagnosis and for the evaluation of CoV-2 vaccination efficacy

229

(the titer of neutralizing antibody present in a serum is a correlate of protection), as well as for

230

preliminary test molecules able to interfere with S, ACE2 and TMPRRS2 interaction. Before

231

attempting the generation of a Lenti-based pseudovirus displaying CoV-2 S on its surface, it

232

was indispensable to generate an appropriate expression cassette capable to drive an efficient

233

expression of S, accommodated on the pseudovirus envelope surface. The cytoplasmic tails of

234

some CoV S proteins contain an Endoplasmic Reticulum Retrieval Signal (ERRS) that can

235

retrieve S proteins from the Golgi to the Endoplasmic Reticulum (ER). This process is thought

236

to accumulate S proteins at the CoV budding site, the ER-Golgi Intermediate Compartment

237

(ERGIC), and to facilitate S protein incorporation into virions [13,14]. In contrast to

238

Coronaviruses, Lentiviruses assemble and buds at the cell surface [15], therefore truncation of

239

the S-protein cytoplasmic tail may increase cell surface levels and/or enable incorporation by

240

alleviating structural incompatibility of the S-protein cytoplasmic tail and lentivirus proteins.

241

CoV-2 S ORF sequence (https://www.ncbi.nlm.nih.gov/protein/1791269090) was deprived of

242

its last 57 bp, coding for a predicted ERRS (KFDEDDSEPVLKGVKLHYT) [13] and

243

substituted with the Hemoagglutinin (HA) tag. The so designed ORF (S-ΔRS-HA) was human

244

codon usage adapted, with the use of the Jcat codon adaptation tool (http://www.jcat.de/), to

245

change nucleotide codon composition to a composition based on human genome codon usage.

246

The degeneracy of the genetic code leads to a situation whereby most of the amino acids can

247

be encoded by two to six synonymous codons. The synonymous codons are not equally utilized

248

to encode the amino acids, thus resulting in phenomenon of codon usage bias. Since codon

249

usage bias has been shown to correlate with gene expression level, it has been proposed as an

250

important design parameter for enhancing recombinant protein production in heterologous host

251

expression [16]. The GC content of S-ΔRS-HA is 37% and adaptation to the human genome

252

codon usage shifted the GC content from 37% up to 63% (Supplementary Fig. 2). Although we

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

11
253

did not compare the adapted S-ΔRS-HA ORF with the un-adapted one in terms of expression

254

efficiency, previous studies have shown that GC-rich genes in mammalian cells can be

255

expressed 100-fold more efficiently than their GC-poor counterpart due to increased steady-

256

state mRNA levels [17]. S-ΔRS-HA was chemically synthetized and integrated in a transfer

257

vector under the transcriptional guide of the Immediate Early gene promoter of human

258

Cytomegalovirus (CMV) and followed by an IRES, the puromycin drug resistance gene and

259

the Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element (WPRE) (pLV-

260

CMV-(S-ΔRS-HA)-IRES-Puro-WPRE (Fig. 1A and Supplementary Fig. 3 for complete

261

sequence).

262

pLV-CMV-(S-ΔRS-HA)-IRES-Puro-WPRE transfected cells successfully expressed S-ΔRS-

263

HA

264

HEK/ACE2/TMPRRS2/Puro where transiently cotransfected with pLV-CMV-(S-ΔRS-HA)-

265

IRES-Puro-WPRE and pEGFP-C1, a construct delivering Enhanced Green Fluorescent Protein

266

(EGFP), large syncytia were observed (Fig. 1C). This syncytiogenic effect was attributable to

267

the interaction between S, ACE2 and TMPRRS2, which recapitulated the bonafide fusogenic

268

activity of S when is attached to ACE2, proteolytically activated by TMPRSS2 and regulated

269

by Interferon-Induced Transmembrane (IFITMs) proteins [18,19]. An identical result was

270

obtained when HEK/ACE2/TMPRRS2/Puro cells were co-cultivated with pLV-CMV-(S-ΔRS-

271

HA)-IRES-Puro-WPRE and pEGFP-C1 co-transiently transfected HEK293T cells (Fig. 1D).

272

Further, syncytia could be reduced or abrogated if pLV-CMV-(S-ΔRS-HA)-IRES-Puro-WPRE

273

transfected HEK/ACE2/TMPRRS2/Puro cells were treated with human COVID-19

274

convalescent sera containing anti-S antibodies or TMPRSS2 inhibitors (data not shown).

protein

as

shown

by

western

275
276

Generation of a lenti-based pseudovirus.

immunoblotting

(Fig.

1B).

When

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

12
277

Relying on the promising results obtained with pLV-CMV-(S-ΔRS-HA)-IRES-Puro-WPRE

278

construct and HEK/ACE2/TMPRRS2/Puro cell line, the reconstitution of a second generation

279

replicating incompetent lentivirus, pseudotyped with CoV-2 S was attempted. The pLV-EF1α-

280

(turboGFP-Luc2)-WPRE transfer vector, the p8.74 packaging vector and the pLV-CMV-(S-

281

ΔRS-HA)-IRES-Puro-WPRE pseudotyping vector were co-transfected in HEK293T cells.

282

Twenty-four and 48 hours post-transfection, Transfected Cells Supernatant (TCS) were

283

harvested, clarified, filtered, aliquoted, stored at -80 °C and subsequently tested on

284

HEK/ACE2/TMPRRS2/Puro cells and on HEK293T cells as negative control. Since pLV-

285

EF1α-(turboGFP-Luc2)-WPRE transfer vector could simultaneously deliver two reporter

286

genes, turboGFP and a human codon usage adapted luciferase (Luc2), cell transduction could

287

be detected either by fluorescence or luminometry. In fact, when different amount of TCS were

288

tested on different numbers of HEK/ACE2/TMPRRS2/Puro cells, an efficient cell transduction

289

could be observed but not on HEK293T negative control cells (Fig. 2A, 2B and C). Further,

290

bonafide fusogenic activity through syncytia formation could be observed (Fig. 2D and E),

291

recapitulating natural CoV-2 infection. Syncytia formation could be considered a signature of

292

CoV infection and pathogenicity since it can be observed not only in vitro but also in vivo, in

293

lung tissue from people infected with different CoVs, such as SARS-CoV, MERS-CoV or

294

SARS-CoV-2 [19-24].

295
296

Lentivirus-based vector can be pseudotyped with ACE2/TMPRSS2.

297

TMPRSS2 is a serine protease with a class II transmembrane domain, whereas ACE2 is a

298

carboxypeptidase with a class I transmembrane domain and both of them are localized on the

299

cell membrane surface [7] (Supplementary Fig. 4). Based on this information it was reasoned

300

that lentiviral vector particles could potentially be pseudotyped with ACE2/TMPRSS2 and

301

allow pseudovirus penetration into cells expressing CoV-2 S. The pLV-EF1α-(turboGFP-

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

13

vector,

the

p8.74

packaging

vector

and

the

pEF1α-

302

Luc2)-WPRE

303

ACE2/TMPRRS2/Puro pseudotyping vector were co-transfected in HEK293T cells. Twenty-

304

four and 48 hours post transfection TCS were harvested, aliquoted, stored at -80 C° and

305

subsequently tested on pLV-CMV-(S-ΔRS-HA)-IRES-Puro-WPRE transiently or stably

306

transfected HEK/S-ΔRS-HA/Puro cells and on HEK293T cells as negative control. TCS

307

transduction could be observed on HEK/S-ΔRS-HA/Puro cells but not on HEK293T cells

308

negative control cells (Fig. 3A and B). Therefore, a lentivirus-based vector could be

309

pseudotyped with ACE2/TMPRSS2. Worth of note, this kind of pseudotypization and cell

310

transduction did not generate syncytia as observed for the lentivirus-based vector pseudotyped

311

with CoV-2 S. Although the reason of this issue was not investigated, because out of the purpose

312

of this work, it could be assumed that the syncytia formation is an active process in part

313

dependent by a specific intracellular apparatus, contacting the long cytoplasmic tail of ACE2

314

and/or TMPRSS2, present inside the cells but absent inside the pseudotyped lentiviral particles.

315

It was shown that infection with CoV-2 was significantly decreased in cells expressing ACE2

316

mutant versions lacking the cytoplasmic domain [25].

transfer

317
318

Assessment of a pseudovirus neutralization assay.

319

Starting from the availability of a pseudovirus mimicking the interaction of SARS-CoV-2 with

320

target cells, it was of interest to assess a pseudovirus neutralization assay, to be applied for

321

several purposes. The aim of this assay is to overcome the other neutralization assays

322

complexities, such as multiple passages and the addition and removal of reagents and solutions,

323

mainly during sera dilution and detection steps, where cells could detach from the microplate

324

surface and strong errors could be introduced. In our simplified system reagents and solution

325

are only added at each step, while washing steps are absent, from the beginning to the end of

326

the assay.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

14
327

Opaque wall, clear flat bottom 96 well microplates were employed (Supplementary Fig. 5).

328

Opaque walls prevent well-to-well crosstalk for luminometric detection whereas clear flat

329

bottom well direct microscopic monitoring cell growth and/or fluorescence microscope

330

observation of transduced cells expressing a fluorescent reporter gene, in this specific case

331

turboGFP. The neutralization assay was performed with human sera coming from SARS-CoV-

332

2-infected patients, collected after post–symptoms onset, that resulted positive to PCR and

333

ELISA tests. Whereas, sera collected prior to the SARS-CoV-2 emergence (1999) that tested

334

negative in ELISA were used as negative control. First, serial dilution of the sera (plasma from

335

EDTA treated blood can be used too), were incubated for 90 minutes with TCS containing

336

pseudovirus sufficient to achieve approximately 104 Relative Light Units (RLUs) of luciferase

337

signal

338

HEK/ACE2/TMPRRS2/Puro cells were added to each well (Supplementary Fig. 5). As

339

previously mentioned, HEK/ACE2/TMPRRS2/Puro cells do not need to be constantly kept in

340

culture under puromycin selection: a large batch of them can be grown, aliquoted at a suitable

341

concentration, stored at -80 C° or in liquid nitrogen and be immediately ready to use after

342

thawing.

343

ACE2/TMPRRS2/Puro and directly used, obtaining the same result. NT50 could be measured

344

as soon as 48 hours after adding the cells, either by a fluorescence microscope, or by

345

luminometry and simply adding Luciferine in each well (Supplementary Fig. 5 and Fig. 4A and

346

B), without the need of cell lysis and of transferring the lysate to a different microplate.

347

Moreover, light detection can be performed with a Digital Imager for western blotting, BLI, or

348

by a multiwell plate reader luminometer.

349

Thus, a rapid, flexible, reliable, sensitive and cost effective pseudovirus neutralization assay for

350

SARS-CoV-2 was established, where all steps could be performed in the same plate and in a

351

standard BSL2 laboratory, since the pseudovirus is completely safe. With this assay we have

per

well

(usually

Alternatively,

no

more

HEK293T

than

cells

2

can

to

be

10

µL).

Subsequently

electroporated

with

104

pEF1α-

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

15
352

been able to rapidly and cheaply determine the neutralizing potency of mAbs derived from

353

serum or plasma samples in a BSL2 laboratory. Automation and additional miniaturization is

354

certainly possible to further increase throughput. Since serum neutralizing activity has long

355

been identified as a correlate of protection in many viral infection [26], including CoVs [27]

356

and a global CoV-2 vaccination campaign is ongoing, it is absolutely important to have a

357

practical test to assess the outcome of vaccination. In order to meet this need, such test must be

358

rapid, flexible, reliable, sensitive, quantitative, cost effective, safe and easily adapted to

359

different coronaviruses variants.

360
361

Acknowledgement: We would like to thank all the people who decided to donate their blood

362

for the study and Diletta Laccabue, Laboratory of Viral Immunopathology, Unit of Infectious

363

Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, for taking care of the

364

experimental protocol submission to the ethical committee.

365
366

Declaration of interest statement: No potential conflict of interest was reported by the

367

authors.

368
369

Funding details: residual founding from grants unrelated to the present work topic.

370
371

References

372
373
374
375
376
377
378
379
380
381

1.
2.
3.
4.
5.

Han Q, Lin Q, Jin S, et al. Coronavirus 2019-nCoV: A brief perspective from the front line. J
Infect. 2020 Apr;80(4):373-377.
Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020
Apr;580(7805):576-577.
Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications
to phase 3 vaccine candidates. Lancet. 2020 Nov 14;396(10262):1595-1606.
Iacob S, Iacob DG. SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for
a Versatile Virus. Front Pharmacol. 2020;11:1224.
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev
Drug Discov. 2020 Mar;19(3):149-150.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

16
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435

6.
7.

8.
9.
10.

11.
12.

13.
14.

15.
16.
17.
18.

19.
20.

21.
22.

23.

24.

25.

26.
27.

Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARSCoV-2 Spike Glycoprotein. Cell. 2020 Apr 16;181(2):281-292 e6.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2
and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr
16;181(2):271-280 e8.
Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length
human ACE2. Science. 2020 Mar 27;367(6485):1444-1448.
Lin K, Liu M, Ma H, et al. Laboratory biosafety emergency management for SARS-CoV-2. J
Biosaf Biosecur. 2020 Sep 19.
Case JB, Rothlauf PW, Chen RE, et al. Neutralizing Antibody and Soluble ACE2 Inhibition of
a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host
Microbe. 2020 Sep 9;28(3):475-485 e5.
Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for
SARS-CoV-2. Emerg Microbes Infect. 2020 Dec;9(1):680-686.
Crawford KHD, Eguia R, Dingens AS, et al. Protocol and Reagents for Pseudotyping Lentiviral
Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses. 2020 May
6;12(5).
Giroglou T, Cinatl J, Jr., Rabenau H, et al. Retroviral vectors pseudotyped with severe acute
respiratory syndrome coronavirus S protein. J Virol. 2004 Sep;78(17):9007-15.
Ujike M, Huang C, Shirato K, et al. The contribution of the cytoplasmic retrieval signal of
severe acute respiratory syndrome coronavirus to intracellular accumulation of S proteins and
incorporation of S protein into virus-like particles. J Gen Virol. 2016 Aug;97(8):1853-1864.
Jouvenet N, Neil SJD, Bess C, et al. Plasma membrane is the site of productive HIV-1 particle
assembly. Plos Biology. 2006 Dec;4(12):2296-2310.
Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression.
Trends Biotechnol. 2004 Jul;22(7):346-53.
Kudla G, Lipinski L, Caffin F, et al. High guanine and cytosine content increases mRNA levels
in mammalian cells. PLoS Biol. 2006 Jun;4(6):e180.
Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 Receptor ACE2 Is an InterferonStimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets
across Tissues. Cell. 2020 May 28;181(5):1016-1035 e19.
Buchrieser J, Dufloo J, Hubert M, et al. Syncytia formation by SARS-CoV-2-infected cells.
EMBO J. 2020 Oct 13:e106267.
Bussani R, Schneider E, Zentilin L, et al. Persistence of viral RNA, pneumocyte syncytia and
thrombosis are hallmarks of advanced COVID-19 pathology. EBioMedicine. 2020
Nov;61:103104.
Franks TJ, Chong PY, Chui P, et al. Lung pathology of severe acute respiratory syndrome
(SARS): a study of 8 autopsy cases from Singapore. Hum Pathol. 2003 Aug;34(8):743-8.
Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by
a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high
capacity to mediate membrane fusion. Cell Res. 2020 Apr;30(4):343-355.
Matsuyama S, Nagata N, Shirato K, et al. Efficient activation of the severe acute respiratory
syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010
Dec;84(24):12658-64.
Qian Z, Dominguez SR, Holmes KV. Role of the spike glycoprotein of human Middle East
respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation. PLoS
One. 2013;8(10):e76469.
Haga S, Yamamoto N, Nakai-Murakami C, et al. Modulation of TNF-alpha-converting enzyme
by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates
viral entry. Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14.
Plotkin SA. Correlates of Protection Induced by Vaccination. Clinical and Vaccine
Immunology. 2010 Jul;17(7):1055-1065.
Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2
infection and the potential for reinfection. Journal of General Virology. 2020;101(8):791-797.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

17

436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461

Fig. 1. CoV-2 S expression in HEK293T cells. A) Diagram not on scale of pLV-CMV-(S-ΔRSHA)-IRES-Puro-WPRE transfer vector, where functional elements of the construct are
indicated and highlighted with different colours. RSVp (Rous sarcoma virus
enhancer/promoter), 5’LTRΔU3 (Truncated HIV-1 5’ Long terminal repeat), Ψ (HIV-1
packaging signal, RRE (HIV-1 REV response element), cPPT (Central polypurine tract), CMV
(Human cytomegalovirus immediate early enhancer/promoter), Kozak (Kozak’s translation
initiation sequence), S-ΔRS-HA (Human codon usage adapted, HA tagged and retention signal
delete CoV-2 S ORF), IRES (Encephalomyocarditis virus internal ribosomal entry site), Puro
(Puromycin resistant gene ORF), WPRE (Woodchuck hepatitis virus posttranslational
regulatory element), 3’LTRΔU3 (Truncated HIV-1 3’ long terminal repeat; self-inactivation),
SV40 early pA (Simian virus 40 early polyadenylation signal), Amp (Ampicillin resistance
gene, comprising the promoter and ORF) and pUC ori (High copy number pUC origin of
replication). B) Western immunoblotting of pLV-CMV-(S-ΔRS-HA)-IRES-Puro-WPRE
transfected HEK293T cells protein extracts (S-ΔRS-HA; 40 and 20 µg) and pEGFP-C1
transfected HEK293T cells protein extract (GFP; 40 µg) employed as a negative control (-). C)
Representative microscopic image (Phase contrast, Fluorescence and Merged fields; 10X) of
syncytia, generated by co-transfection of HEK/ACE2/TMPRRS2/Puro cells with pLV-CMV(S-ΔRS-HA)-IRES-Puro-WPRE construct and PEGFP-C1. D) Representative microscopic
image (Phase contrast, Fluorescence and Merged fields; 10X) of syncytia, generated by cocultivation of HEK/ACE2/TMPRRS2/Puro cells with pLV-CMV-(S-ΔRS-HA)-IRES-PuroWPRE and pEGFP-C1 co-transiently transfected HEK293T cells.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

18

462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488

Fig. 2. Pseudovirus assembly and transduction. A) Representative images (Phase contrast and
fluorescence; 10X) of HEK/ACE2/TMPRRS2/Puro cells, at different number (1000 and 4000),
transduced with different amount (50 µL, 20 µL and 10 µL) of supernatant containing
pseudovirus.
B)
ChemiDoc
and
IVIS
(C)
luminometric
detection
of
HEK/ACE2/TMPRRS2/Puro cells, at different number (1000, 2000, 3000, 4000, 5000 and
4000), transduced with different amount (50 µL, 20 µL and 10 µL) of supernatant containing
pseudovirus (S Pseudovirus). Negative control was established with HEK293T cells, at
different number (1000, 2000, 3000, 4000, 5000 and 4000) and transduced with 50 µl of the
same supernatant containing pseudovirus (S Pseudovirus). D) Representative images of
syncytia (Phase contrast and fluorescence of the same field; 10X), generated by pseudovirus
transduced HEK/ACE2/TMPRRS2/Puro cells. E) Representative images of a syncytium (Phase
contrast; 10X) generated by pseudovirus transduced HEK/ACE2/TMPRRS2/Puro cells and
stained with Hematoxylin and Eosin (H&E staining).

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

19

489
490
491
492
493
494
495
496
497
498

Fig. 3. Pseudovirus generation with ACE2 and TMPRSS2. A) Representative image (Phase
contrast and Fluorescence of the same field; 10X) of HEK/S-ΔRS-HA/Puro cells (HEK/S) and
HEK293T cells (HEK) transduced with ACE2/TMPRSS2 Pseudovirus. B) Representative 25
cm2 flasks of HEK/S-ΔRS-HA/Puro cells (HEK/S) and HEK293T cells (HEK) transduced with
ACE2/TMPRSS2 Pseudovirus and exposed to the ChemiDoc apparatus. Luminometric
quantification of the lysate of the same cells, expressed as Relative Luciferase Units (RLUs)
and colorimetrically visualized (violet and blue spots) by the luminometer software, during and
after reading. C) Cartoon explaining the lack of syncytia generation by ACE2/TMPRSS2
Pseudovirus.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

20

499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515

Fig. 4. Representative pseudovirus neutralization assay. Six PCR and ELISA CoV2 negative
patients’ representative sera (1 to 6), 3 PCR and ELISA CoV2 positive patients’ sera (7 to 9)
and 2 pre-pandemic sera (collected in the 1998; 10 and 11) were tested. A further negative
control was established without serum (12), which was substituted with complete medium. (A)
Histogram obtained from luminometric detection of transduced cells with pseudovirus. Relative
Luciferase Units (RLUs) were compared and normalized to those derived from wells where
pseudovirus were added in the absence of sera (100%). Neutralization titer 50 (NT50) was
expressed as the maximal dilution of the sera where the reduction of the signal was ≥50%. In
this specific example, the NT50/25µL of the serum 7 is 1:256, that of the serum 8 is 1:128 and
that of the serum 9 is 1:64. However, because the titer was measured on 25 µL, the apparent
NT50 has to be multiplied per 40 to get the normalized NT50/mL. Therefore, the NT50/mL of the
sera 7 is 1:10256, that of the serum 8 is 1:5120 and that of the serum 9 is 1:2560. (B)
Colorimetric visualization of the RLUs displayed by the luminometer software, during and after
reading.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

21

516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547

Supplementary Figure 1. Diagram not on scale of pEF1α-ACE2/TMPRSS2/Puro construct,
where functional elements of the construct are indicated and highlighted with different colours.
EF1α (human Elongation Factor 1 alpha promoter), Kozak (Kozak’s translation initiation
sequence), ACE2 (Human Angiotensin Converting Enzyme 2 ORF), IRES
(Encephalomyocarditis virus internal ribosomal entry site), TMPRSS2 (human Transmembrane
Protease Serine 2), Puro (Puromycin resistance gene ORF), pUC ori (High copy number pUC
origin of replication) SV40 pA (Simian virus 40 early polyadenylation signal) and Amp
(Ampicillin resistance gene, comprising the prokaryotic promoter and ORF).
pEF1α-ACE2/TMPRRS2/Puro complete sequence
CAACTTTGTATAGAAAAGTTGGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC
ACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGG
CGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGG
GGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTAT
GGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAG
CTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCT
CGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCAC
CTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCT
GCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACT
GGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGT
TCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCT
GGCCGGCCTGCTCTGGTGCCTGGTCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCA
AGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCT
GCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACA
CAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGG
GCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGG
GGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGG
CCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGG

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

22
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608

TTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGA
CAAGTTTGTACAAAAAAGCAGGCTGCCACCATGTCAAGCTCTTCCTGGCTCCTTCTCAGC
CTTGTTGCTGTAACTGCTGCTCAGTCCACCATTGAGGAACAGGCCAAGACATTTTTGGAC
AAGTTTAACCACGAAGCCGAAGACCTGTTCTATCAAAGTTCACTTGCTTCTTGGAATTAT
AACACCAATATTACTGAAGAGAATGTCCAAAACATGAATAATGCTGGGGACAAATGGTCT
GCCTTTTTAAAGGAACAGTCCACACTTGCCCAAATGTATCCACTACAAGAAATTCAGAAT
CTCACAGTCAAGCTTCAGCTGCAGGCTCTTCAGCAAAATGGGTCTTCAGTGCTCTCAGAA
GACAAGAGCAAACGGTTGAACACAATTCTAAATACAATGAGCACCATCTACAGTACTGGA
AAAGTTTGTAACCCAGATAATCCACAAGAATGCTTATTACTTGAACCAGGTTTGAATGAA
ATAATGGCAAACAGTTTAGACTACAATGAGAGGCTCTGGGCTTGGGAAAGCTGGAGATCT
GAGGTCGGCAAGCAGCTGAGGCCATTATATGAAGAGTATGTGGTCTTGAAAAATGAGATG
GCAAGAGCAAATCATTATGAGGACTATGGGGATTATTGGAGAGGAGACTATGAAGTAAAT
GGGGTAGATGGCTATGACTACAGCCGCGGCCAGTTGATTGAAGATGTGGAACATACCTTT
GAAGAGATTAAACCATTATATGAACATCTTCATGCCTATGTGAGGGCAAAGTTGATGAAT
GCCTATCCTTCCTATATCAGTCCAATTGGATGCCTCCCTGCTCATTTGCTTGGTGATATG
TGGGGTAGATTTTGGACAAATCTGTACTCTTTGACAGTTCCCTTTGGACAGAAACCAAAC
ATAGATGTTACTGATGCAATGGTGGACCAGGCCTGGGATGCACAGAGAATATTCAAGGAG
GCCGAGAAGTTCTTTGTATCTGTTGGTCTTCCTAATATGACTCAAGGATTCTGGGAAAAT
TCCATGCTAACGGACCCAGGAAATGTTCAGAAAGCAGTCTGCCATCCCACAGCTTGGGAC
CTGGGGAAGGGCGACTTCAGGATCCTTATGTGCACAAAGGTGACAATGGACGACTTCCTG
ACAGCTCATCATGAGATGGGGCATATCCAGTATGATATGGCATATGCTGCACAACCTTTT
CTGCTAAGAAATGGAGCTAATGAAGGATTCCATGAAGCTGTTGGGGAAATCATGTCACTT
TCTGCAGCCACACCTAAGCATTTAAAATCCATTGGTCTTCTGTCACCCGATTTTCAAGAA
GACAATGAAACAGAAATAAACTTCCTGCTCAAACAAGCACTCACGATTGTTGGGACTCTG
CCATTTACTTACATGTTAGAGAAGTGGAGGTGGATGGTCTTTAAAGGGGAAATTCCCAAA
GACCAGTGGATGAAAAAGTGGTGGGAGATGAAGCGAGAGATAGTTGGGGTGGTGGAACCT
GTGCCCCATGATGAAACATACTGTGACCCCGCATCTCTGTTCCATGTTTCTAATGATTAC
TCATTCATTCGATATTACACAAGGACCCTTTACCAATTCCAGTTTCAAGAAGCACTTTGT
CAAGCAGCTAAACATGAAGGCCCTCTGCACAAATGTGACATCTCAAACTCTACAGAAGCT
GGACAGAAACTGTTCAATATGCTGAGGCTTGGAAAATCAGAACCCTGGACCCTAGCATTG
GAAAATGTTGTAGGAGCAAAGAACATGAATGTAAGGCCACTGCTCAACTACTTTGAGCCC
TTATTTACCTGGCTGAAAGACCAGAACAAGAATTCTTTTGTGGGATGGAGTACCGACTGG
AGTCCATATGCAGACCAAAGCATCAAAGTGAGGATAAGCCTAAAATCAGCTCTTGGAGAT
AAAGCATATGAATGGAACGACAATGAAATGTACCTGTTCCGATCATCTGTTGCATATGCT
ATGAGGCAGTACTTTTTAAAAGTAAAAAATCAGATGATTCTTTTTGGGGAGGAGGATGTG
CGAGTGGCTAATTTGAAACCAAGAATCTCCTTTAATTTCTTTGTCACTGCACCTAAAAAT
GTGTCTGATATCATTCCTAGAACTGAAGTTGAAAAGGCCATCAGGATGTCCCGGAGCCGT
ATCAATGATGCTTTCCGTCTGAATGACAACAGCCTAGAGTTTCTGGGGATACAGCCAACA
CTTGGACCTCCTAACCAGCCCCCTGTTTCCATATGGCTGATTGTTTTTGGAGTTGTGATG
GGAGTGATAGTGGTTGGCATTGTCATCCTGATCTTCACTGGGATCAGAGATCGGAAGAAG
AAAAATAAAGCAAGAAGTGGAGAAAATCCTTATGCCTCCATCGATATTAGCAAAGGAGAA
AATAATCCAGGATTCCAAAACACTGATGATGTTCAGACCTCCTTTTAGGCCCCTCTCCCT
CCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCT
ATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCC
CTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTC
TGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTG
TAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAA
AGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTT
GGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGG
ATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTA
CATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTT
TCCTTTGAAAAACACGATGATAATATGGCCACAACCATGCCCCCTGCCCCGCCCGGAGGT
GAAAGCGGGTGTGAGGAGCGCGGCGCGGCAGGTCATATTGAACATTCCAGATACCTATCA
TTACTCGATGCTGTTGATAACAGCAAGATGGCTTTGAACTCAGGGTCACCACCAGCTATT
GGACCTTACTATGAAAACCATGGATACCAACCGGAAAACCCCTATCCCGCACAGCCCACT
GTGGTCCCCACTGTCTACGAGGTGCATCCGGCTCAGTACTACCCGTCCCCCGTGCCCCAG
TACGCCCCGAGGGTCCTGACGCAGGCTTCCAACCCCGTCGTCTGCACGCAGCCCAAATCC
CCATCCGGGACAGTGTGCACCTCAAAGACTAAGAAAGCACTGTGCATCACCTTGACCCTG
GGGACCTTCCTCGTGGGAGCTGCGCTGGCCGCTGGCCTACTCTGGAAGTTCATGGGCAGC
AAGTGCTCCAACTCTGGGATAGAGTGCGACTCCTCAGGTACCTGCATCAACCCCTCTAAC
TGGTGTGATGGCGTGTCACACTGCCCCGGCGGGGAGGACGAGAATCGGTGTGTTCGCCTC

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

23
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669

TACGGACCAAACTTCATCCTTCAGGTGTACTCATCTCAGAGGAAGTCCTGGCACCCTGTG
TGCCAAGACGACTGGAACGAGAACTACGGGCGGGCGGCCTGCAGGGACATGGGCTATAAG
AATAATTTTTACTCTAGCCAAGGAATAGTGGATGACAGCGGATCCACCAGCTTTATGAAA
CTGAACACAAGTGCCGGCAATGTCGATATCTATAAAAAACTGTACCACAGTGATGCCTGT
TCTTCAAAAGCAGTGGTTTCTTTACGCTGTATAGCCTGCGGGGTCAACTTGAACTCAAGC
CGCCAGAGCAGGATTGTGGGCGGCGAGAGCGCGCTCCCGGGGGCCTGGCCCTGGCAGGTC
AGCCTGCACGTCCAGAACGTCCACGTGTGCGGAGGCTCCATCATCACCCCCGAGTGGATC
GTGACAGCCGCCCACTGCGTGGAAAAACCTCTTAACAATCCATGGCATTGGACGGCATTT
GCGGGGATTTTGAGACAATCTTTCATGTTCTATGGAGCCGGATACCAAGTAGAAAAAGTG
ATTTCTCATCCAAATTATGACTCCAAGACCAAGAACAATGACATTGCGCTGATGAAGCTG
CAGAAGCCTCTGACTTTCAACGACCTAGTGAAACCAGTGTGTCTGCCCAACCCAGGCATG
ATGCTGCAGCCAGAACAGCTCTGCTGGATTTCCGGGTGGGGGGCCACCGAGGAGAAAGGG
AAGACCTCAGAAGTGCTGAACGCTGCCAAGGTGCTTCTCATTGAGACACAGAGATGCAAC
AGCAGATATGTCTATGACAACCTGATCACACCAGCCATGATCTGTGCCGGCTTCCTGCAG
GGGAACGTCGATTCTTGCCAGGGTGACAGTGGAGGGCCTCTGGTCACTTCGAAGAACAAT
ATCTGGTGGCTGATAGGGGATACAAGCTGGGGTTCTGGCTGTGCCAAAGCTTACAGACCA
GGAGTGTACGGGAATGTGATGGTATTCACGGACTGGATTTATCGACAAATGAGGGCAGAC
GGCTAAACCCAGCTTTCTTGTACAAAGTGGGCCCCTCTCCCTCCCCCCCCCCTAACGTTA
CTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCA
TATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCA
TTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGG
AAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGC
AGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATA
CACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAG
TCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCC
ATTGTATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGT
TAAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGAT
GATAATATGGCCACAACCATGACCGAGTACAAGCCCACGGTGCGCCTCGCCACCCGCGAC
GACGTCCCCAGGGCCGTACGCACCCTCGCCGCCGCGTTCGCCGACTACCCCGCCACGCGC
CACACCGTCGATCCGGACCGCCACATCGAGCGGGTCACCGAGCTGCAAGAACTCTTCCTC
ACGCGCGTCGGGCTCGACATCGGCAAGGTGTGGGTCGCGGACGACGGCGCCGCGGTGGCG
GTCTGGACCACGCCGGAGAGCGTCGAAGCGGGGGCGGTGTTCGCCGAGATCGGCCCGCGC
ATGGCCGAGTTGAGCGGTTCCCGGCTGGCCGCGCAGCAACAGATGGAAGGCCTCCTGGCG
CCGCACCGGCCCAAGGAGCCCGCGTGGTTCCTGGCCACCGTCGGCGTCTCGCCCGACCAC
CAGGGCAAGGGTCTGGGCAGCGCCGTCGTGCTCCCCGGAGTGGAGGCGGCCGAGCGCGCC
GGGGTGCCCGCCTTCCTGGAGACCTCCGCGCCCCGCAACCTCCCCTTCTACGAGCGGCTC
GGCTTCACCGTCACCGCCGACGTCGAGGTGCCCGAAGGACCGCGCACCTGGTGCATGACC
CGCAAGCCCGGTGCCTGACAACTTTATTATACATAGTTGATGGCCGGCCGCTTCGAGCAG
ACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAAT
GCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATA
AACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGG
AGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAGCGGCCGCGGCGCTCTTCCGC
TTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCA
CTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTG
AGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCA
TAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAA
CCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCC
TGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCTCTTCGGGAAGCGTGGC
GCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCT
GGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCG
TCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAG
GATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTA
CGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGG
AAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTT
TGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTT
TTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAG
ATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAAT
CTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACC
TATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGAT
AACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCC
ACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAG

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

24
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703

AAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAG
AGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGT
GGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCG
AGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGT
TGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTC
TCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTC
ATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAA
TACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCG
AAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACC
CAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAG
GCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTT
CCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATT
TGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCC
ACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCAC
GAGGCCCTTTCGTCGGCGCGCCGCGGCCGC

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

25
704

Supplementary Figure 2.

705

S-ΔRS-HA human adapted ORF sequence

706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748

ATGTTCGTGTTCCTGGTGCTGCTGCCCCTGGTGAGCAGCCAGTGCGTGAACCTGACCACCCGCACCCAGCTGCCCCCCGCCTACACCAAC
AGCTTCACCCGCGGCGTGTACTACCCCGACAAGGTGTTCCGCAGCAGCGTGCTGCACAGCACCCAGGACCTGTTCCTGCCCTTCTTCAGC
AACGTGACCTGGTTCCACGCCATCCACGTGAGCGGCACCAACGGCACCAAGCGCTTCGACAACCCCGTGCTGCCCTTCAACGACGGCGT
GTACTTCGCCAGCACCGAGAAGAGCAACATCATCCGCGGCTGGATCTTCGGCACCACCCTGGACAGCAAGACCCAGAGCCTGCTGATCG
TGAACAACGCCACCAACGTGGTGATCAAGGTGTGCGAGTTCCAGTTCTGCAACGACCCCTTCCTGGGCGTGTACTACCACAAGAACAAC
AAGAGCTGGATGGAGAGCGAGTTCCGCGTGTACAGCAGCGCCAACAACTGCACCTTCGAGTACGTGAGCCAGCCCTTCCTGATGGACCT
GGAGGGCAAGCAGGGCAACTTCAAGAACCTGCGCGAGTTCGTGTTCAAGAACATCGACGGCTACTTCAAGATCTACAGCAAGCACACCC
CCATCAACCTGGTGCGCGACCTGCCCCAGGGCTTCAGCGCCCTGGAGCCCCTGGTGGACCTGCCCATCGGCATCAACATCACCCGCTTCC
AGACCCTGCTGGCCCTGCACCGCAGCTACCTGACCCCCGGCGACAGCAGCAGCGGCTGGACCGCCGGCGCCGCCGCCTACTACGTGGGC
TACCTGCAGCCCCGCACCTTCCTGCTGAAGTACAACGAGAACGGCACCATCACCGACGCCGTGGACTGCGCCCTGGACCCCCTGAGCGA
GACCAAGTGCACCCTGAAGAGCTTCACCGTGGAGAAGGGCATCTACCAGACCAGCAACTTCCGCGTGCAGCCCACCGAGAGCATCGTGC
GCTTCCCCAACATCACCAACCTGTGCCCCTTCGGCGAGGTGTTCAACGCCACCCGCTTCGCCAGCGTGTACGCCTGGAACCGCAAGCGCA
TCAGCAACTGCGTGGCCGACTACAGCGTGCTGTACAACAGCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGAGCCCCACCAAGCTG
AACGACCTGTGCTTCACCAACGTGTACGCCGACAGCTTCGTGATCCGCGGCGACGAGGTGCGCCAGATCGCCCCCGGCCAGACCGGCAA
GATCGCCGACTACAACTACAAGCTGCCCGACGACTTCACCGGCTGCGTGATCGCCTGGAACAGCAACAACCTGGACAGCAAGGTGGGC
GGCAACTACAACTACCTGTACCGCCTGTTCCGCAAGAGCAACCTGAAGCCCTTCGAGCGCGACATCAGCACCGAGATCTACCAGGCCGG
CAGCACCCCCTGCAACGGCGTGGAGGGCTTCAACTGCTACTTCCCCCTGCAGAGCTACGGCTTCCAGCCCACCAACGGCGTGGGCTACCA
GCCCTACCGCGTGGTGGTGCTGAGCTTCGAGCTGCTGCACGCCCCCGCCACCGTGTGCGGCCCCAAGAAGAGCACCAACCTGGTGAAGA
ACAAGTGCGTGAACTTCAACTTCAACGGCCTGACCGGCACCGGCGTGCTGACCGAGAGCAACAAGAAGTTCCTGCCCTTCCAGCAGTTC
GGCCGCGACATCGCCGACACCACCGACGCCGTGCGCGACCCCCAGACCCTGGAGATCCTGGACATCACCCCCTGCAGCTTCGGCGGCGT
GAGCGTGATCACCCCCGGCACCAACACCAGCAACCAGGTGGCCGTGCTGTACCAGGACGTGAACTGCACCGAGGTGCCCGTGGCCATCC
ACGCCGACCAGCTGACCCCCACCTGGCGCGTGTACAGCACCGGCAGCAACGTGTTCCAGACCCGCGCCGGCTGCCTGATCGGCGCCGAG
CACGTGAACAACAGCTACGAGTGCGACATCCCCATCGGCGCCGGCATCTGCGCCAGCTACCAGACCCAGACCAACAGCCCCCGCCGCGC
CCGCAGCGTGGCCAGCCAGAGCATCATCGCCTACACCATGAGCCTGGGCGCCGAGAACAGCGTGGCCTACAGCAACAACAGCATCGCC
ATCCCCACCAACTTCACCATCAGCGTGACCACCGAGATCCTGCCCGTGAGCATGACCAAGACCAGCGTGGACTGCACCATGTACATCTGC
GGCGACAGCACCGAGTGCAGCAACCTGCTGCTGCAGTACGGCAGCTTCTGCACCCAGCTGAACCGCGCCCTGACCGGCATCGCCGTGGA
GCAGGACAAGAACACCCAGGAGGTGTTCGCCCAGGTGAAGCAGATCTACAAGACCCCCCCCATCAAGGACTTCGGCGGCTTCAACTTCA
GCCAGATCCTGCCCGACCCCAGCAAGCCCAGCAAGCGCAGCTTCATCGAGGACCTGCTGTTCAACAAGGTGACCCTGGCCGACGCCGGC
TTCATCAAGCAGTACGGCGACTGCCTGGGCGACATCGCCGCCCGCGACCTGATCTGCGCCCAGAAGTTCAACGGCCTGACCGTGCTGCC
CCCCCTGCTGACCGACGAGATGATCGCCCAGTACACCAGCGCCCTGCTGGCCGGCACCATCACCAGCGGCTGGACCTTCGGCGCCGGCG
CCGCCCTGCAGATCCCCTTCGCCATGCAGATGGCCTACCGCTTCAACGGCATCGGCGTGACCCAGAACGTGCTGTACGAGAACCAGAAG
CTGATCGCCAACCAGTTCAACAGCGCCATCGGCAAGATCCAGGACAGCCTGAGCAGCACCGCCAGCGCCCTGGGCAAGCTGCAGGACG
TGGTGAACCAGAACGCCCAGGCCCTGAACACCCTGGTGAAGCAGCTGAGCAGCAACTTCGGCGCCATCAGCAGCGTGCTGAACGACAT
CCTGAGCCGCCTGGACAAGGTGGAGGCCGAGGTGCAGATCGACCGCCTGATCACCGGCCGCCTGCAGAGCCTGCAGACCTACGTGACC
CAGCAGCTGATCCGCGCCGCCGAGATCCGCGCCAGCGCCAACCTGGCCGCCACCAAGATGAGCGAGTGCGTGCTGGGCCAGAGCAAGC
GCGTGGACTTCTGCGGCAAGGGCTACCACCTGATGAGCTTCCCCCAGAGCGCCCCCCACGGCGTGGTGTTCCTGCACGTGACCTACGTG
CCCGCCCAGGAGAAGAACTTCACCACCGCCCCCGCCATCTGCCACGACGGCAAGGCCCACTTCCCCCGCGAGGGCGTGTTCGTGAGCAA
CGGCACCCACTGGTTCGTGACCCAGCGCAACTTCTACGAGCCCCAGATCATCACCACCGACAACACCTTCGTGAGCGGCAACTGCGACGT
GGTGATCGGCATCGTGAACAACACCGTGTACGACCCCCTGCAGCCCGAGCTGGACAGCTTCAAGGAGGAGCTGGACAAGTACTTCAAG
AACCACACCAGCCCCGACGTGGACCTGGGCGACATCAGCGGCATCAACGCCAGCGTGGTGAACATCCAGAAGGAGATCGACCGCCTGA
ACGAGGTGGCCAAGAACCTGAACGAGAGCCTGATCGACCTGCAGGAGCTGGGCAAGTACGAGCAGTACATCAAGTGGCCCTGGTACAT
CTGGCTGGGCTTCATCGCCGGCCTGATCGCCATCGTGATGGTGACCATCATGCTGTGCTGCATGACCAGCTGCTGCAGCTGCCTGAAGG
GCTGCTGCAGCTGCGGCAGCTGCTGCTACCCCTACGACGTGCCCGACTACGCCTAA

749

Biscistronic turboGFP-IRES-Luc2 ORF

750
751
752
753
754
755
756
757
758

ATGCCCGCCATGAAGATCGAGTGCCGCATCACCGGCACCCTGAACGGCGTGGAGTTCGAGCTGGTGGGCGGCGGAGAGGGCACCCCCG
AGCAGGGCCGCATGACCAACAAGATGAAGAGCACCAAAGGCGCCCTGACCTTCAGCCCCTACCTGCTGAGCCACGTGATGGGCTACGG
CTTCTACCACTTCGGCACCTACCCCAGCGGCTACGAGAACCCCTTCCTGCACGCCATCAACAACGGCGGCTACACCAACACCCGCATCGA
GAAGTACGAGGACGGCGGCGTGCTGCACGTGAGCTTCAGCTACCGCTACGAGGCCGGCCGCGTGATCGGCGACTTCAAGGTGGTGGGC
ACCGGCTTCCCCGAGGACAGCGTGATCTTCACCGACAAGATCATCCGCAGCAACGCCACCGTGGAGCACCTGCACCCCATGGGCGATAA
CGTGCTGGTGGGCAGCTTCGCCCGCACCTTCAGCCTGCGCGACGGCGGCTACTACAGCTTCGTGGTGGACAGCCACATGCACTTCAAGA
GCGCCATCCACCCCAGCATCCTGCAGAACGGGGGCCCCATGTTCGCCTTCCGCCGCGTGGAGGAGCTGCACAGCAACACCGAGCTGGGC
ATCGTGGAGTACCAGCACGCCTTCAAGACCCCCATCGCCTTCGCCAGATCTCGAGCTCGATGAACCCAGCTTTCTTGTACAAAGTGGGCC
CCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTG

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

26
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784

785
786
787
788
789
790
791
792
793
794
795
796

CCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATG
CAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCG
GAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACG
TTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCAT
TGTATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCACGGG
GACGTGGTTTTCCTTTGAAAAACACGATGATAATATGGCCACAACCATGGAAGATGCCAAAAACATTAAGAAGGGCCCAGCGCCATTCT
ACCCACTCGAAGACGGGACCGCCGGCGAGCAGCTGCACAAAGCCATGAAGCGCTACGCCCTGGTGCCCGGCACCATCGCCTTTACCGAC
GCACATATCGAGGTGGACATTACCTACGCCGAGTACTTCGAGATGAGCGTTCGGCTGGCAGAAGCTATGAAGCGCTATGGGCTGAATAC
AAACCATCGGATCGTGGTGTGCAGCGAGAATAGCTTGCAGTTCTTCATGCCCGTGTTGGGTGCCCTGTTCATCGGTGTGGCTGTGGCCCC
AGCTAACGACATCTACAACGAGCGCGAGCTGCTGAACAGCATGGGCATCAGCCAGCCCACCGTCGTATTCGTGAGCAAGAAAGGGCTG
CAAAAGATCCTCAACGTGCAAAAGAAGCTACCGATCATACAAAAGATCATCATCATGGATAGCAAGACCGACTACCAGGGCTTCCAAAG
CATGTACACCTTCGTGACTTCCCATTTGCCACCCGGCTTCAACGAGTACGACTTCGTGCCCGAGAGCTTCGACCGGGACAAAACCATCGC
CCTGATCATGAACAGTAGTGGCAGTACCGGATTGCCCAAGGGCGTAGCCCTACCGCACCGCACCGCTTGTGTCCGATTCAGTCATGCCCG
CGACCCCATCTTCGGCAACCAGATCATCCCCGACACCGCTATCCTCAGCGTGGTGCCATTTCACCACGGCTTCGGCATGTTCACCACGCTG
GGCTACTTGATCTGCGGCTTTCGGGTCGTGCTCATGTACCGCTTCGAGGAGGAGCTATTCTTGCGCAGCTTGCAAGACTATAAGATTCAA
TCTGCCCTGCTGGTGCCCACACTATTTAGCTTCTTCGCTAAGAGCACTCTCATCGACAAGTACGACCTAAGCAACTTGCACGAGATCGCCA
GCGGCGGGGCGCCGCTCAGCAAGGAGGTAGGTGAGGCCGTGGCCAAACGCTTCCACCTACCAGGCATCCGCCAGGGCTACGGCCTGAC
AGAAACAACCAGCGCCATTCTGATCACCCCCGAAGGGGACGACAAGCCTGGCGCAGTAGGCAAGGTGGTGCCCTTCTTCGAGGCTAAG
GTGGTGGACTTGGACACCGGTAAGACACTGGGTGTGAACCAGCGCGGCGAGCTGTGCGTCCGTGGCCCCATGATCATGAGCGGCTACG
TTAACAACCCCGAGGCTACAAACGCTCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCA
CTTCTTCATCGTGGACCGGCTGAAGAGCCTGATCAAATACAAGGGCTACCAGGTAGCCCCAGCCGAACTGGAGAGCATCCTGCTGCAAC
ACCCCAACATCTTCGACGCCGGGGTCGCCGGCCTGCCCGACGACGATGCCGGCGAGCTGCCCGCCGCAGTCGTCGTGCTGGAACACGGT
AAAACCATGACCGAGAAGGAGATCGTGGACTATGTGGCCAGCCAGGTTACAACCGCCAAGAAGCTGCGCGGTGGTGTTGTGTTCGTGG
ACGAGGTGCCTAAAGGACTGACCGGCAAGTTGGACGCCCGCAAGATCCGCGAGATTCTCATTAAGGCCAAGAAGGGCGGCAAGATCGC
CGTGTAA

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

27
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857

Supplementary Figure 3
pLV-CMV-(S-ΔRS-HA)-IRES-Puro-WPRE complete sequence
AATGTAGTCTTATGCAATACTCTTGTAGTCTTGCAACATGGTAACGATGAGTTAGCAACA
TGCCTTACAAGGAGAGAAAAAGCACCGTGCATGCCGATTGGTGGAAGTAAGGTGGTACGA
TCGTGCCTTATTAGGAAGGCAACAGACGGGTCTGACATGGATTGGACGAACCACTGAATT
GCCGCATTGCAGAGATATTGTATTTAAGTGCCTAGCTCGATACATAAACGGGTCTCTCTG
GTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCC
TCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGG
TAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCG
AACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTT
GCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTG
ACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGA
ATTAGATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTA
AAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTA
GAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGA
TCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGG
ATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGT
AAGACCACCGCACAGCAAGCGGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGA
CAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGC
ACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGC
TTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCT
GACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAG
GGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCA
GGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGG
TTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAA
ATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAA
TTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGA
ACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAA
TTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAAT
AGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTT
TCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGG
TGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGCTA
GCTTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATA
ATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTT
ACTAGTATCAACTTTGTATAGAAAAGTTGTAGTTATTAATAGTAATCAATTACGGGGTCA
TTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCT
GGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTA
ACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCAC
TTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGT
AAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAG
TACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAAT
GGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAAT
GGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCC
CCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGT
TTAGTGAACCGTCAGATCCAAGTTTGTACAAAAAAGCAGGCTGCCACCATGTTCGTGTTC
CTGGTGCTGCTGCCCCTGGTGAGCAGCCAGTGCGTGAACCTGACCACCCGCACCCAGCTG
CCCCCCGCCTACACCAACAGCTTCACCCGCGGCGTGTACTACCCCGACAAGGTGTTCCGC
AGCAGCGTGCTGCACAGCACCCAGGACCTGTTCCTGCCCTTCTTCAGCAACGTGACCTGG
TTCCACGCCATCCACGTGAGCGGCACCAACGGCACCAAGCGCTTCGACAACCCCGTGCTG
CCCTTCAACGACGGCGTGTACTTCGCCAGCACCGAGAAGAGCAACATCATCCGCGGCTGG
ATCTTCGGCACCACCCTGGACAGCAAGACCCAGAGCCTGCTGATCGTGAACAACGCCACC
AACGTGGTGATCAAGGTGTGCGAGTTCCAGTTCTGCAACGACCCCTTCCTGGGCGTGTAC
TACCACAAGAACAACAAGAGCTGGATGGAGAGCGAGTTCCGCGTGTACAGCAGCGCCAAC
AACTGCACCTTCGAGTACGTGAGCCAGCCCTTCCTGATGGACCTGGAGGGCAAGCAGGGC
AACTTCAAGAACCTGCGCGAGTTCGTGTTCAAGAACATCGACGGCTACTTCAAGATCTAC
AGCAAGCACACCCCCATCAACCTGGTGCGCGACCTGCCCCAGGGCTTCAGCGCCCTGGAG
CCCCTGGTGGACCTGCCCATCGGCATCAACATCACCCGCTTCCAGACCCTGCTGGCCCTG
CACCGCAGCTACCTGACCCCCGGCGACAGCAGCAGCGGCTGGACCGCCGGCGCCGCCGCC
TACTACGTGGGCTACCTGCAGCCCCGCACCTTCCTGCTGAAGTACAACGAGAACGGCACC
ATCACCGACGCCGTGGACTGCGCCCTGGACCCCCTGAGCGAGACCAAGTGCACCCTGAAG

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

28
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918

AGCTTCACCGTGGAGAAGGGCATCTACCAGACCAGCAACTTCCGCGTGCAGCCCACCGAG
AGCATCGTGCGCTTCCCCAACATCACCAACCTGTGCCCCTTCGGCGAGGTGTTCAACGCC
ACCCGCTTCGCCAGCGTGTACGCCTGGAACCGCAAGCGCATCAGCAACTGCGTGGCCGAC
TACAGCGTGCTGTACAACAGCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGAGCCCC
ACCAAGCTGAACGACCTGTGCTTCACCAACGTGTACGCCGACAGCTTCGTGATCCGCGGC
GACGAGGTGCGCCAGATCGCCCCCGGCCAGACCGGCAAGATCGCCGACTACAACTACAAG
CTGCCCGACGACTTCACCGGCTGCGTGATCGCCTGGAACAGCAACAACCTGGACAGCAAG
GTGGGCGGCAACTACAACTACCTGTACCGCCTGTTCCGCAAGAGCAACCTGAAGCCCTTC
GAGCGCGACATCAGCACCGAGATCTACCAGGCCGGCAGCACCCCCTGCAACGGCGTGGAG
GGCTTCAACTGCTACTTCCCCCTGCAGAGCTACGGCTTCCAGCCCACCAACGGCGTGGGC
TACCAGCCCTACCGCGTGGTGGTGCTGAGCTTCGAGCTGCTGCACGCCCCCGCCACCGTG
TGCGGCCCCAAGAAGAGCACCAACCTGGTGAAGAACAAGTGCGTGAACTTCAACTTCAAC
GGCCTGACCGGCACCGGCGTGCTGACCGAGAGCAACAAGAAGTTCCTGCCCTTCCAGCAG
TTCGGCCGCGACATCGCCGACACCACCGACGCCGTGCGCGACCCCCAGACCCTGGAGATC
CTGGACATCACCCCCTGCAGCTTCGGCGGCGTGAGCGTGATCACCCCCGGCACCAACACC
AGCAACCAGGTGGCCGTGCTGTACCAGGACGTGAACTGCACCGAGGTGCCCGTGGCCATC
CACGCCGACCAGCTGACCCCCACCTGGCGCGTGTACAGCACCGGCAGCAACGTGTTCCAG
ACCCGCGCCGGCTGCCTGATCGGCGCCGAGCACGTGAACAACAGCTACGAGTGCGACATC
CCCATCGGCGCCGGCATCTGCGCCAGCTACCAGACCCAGACCAACAGCCCCCGCCGCGCC
CGCAGCGTGGCCAGCCAGAGCATCATCGCCTACACCATGAGCCTGGGCGCCGAGAACAGC
GTGGCCTACAGCAACAACAGCATCGCCATCCCCACCAACTTCACCATCAGCGTGACCACC
GAGATCCTGCCCGTGAGCATGACCAAGACCAGCGTGGACTGCACCATGTACATCTGCGGC
GACAGCACCGAGTGCAGCAACCTGCTGCTGCAGTACGGCAGCTTCTGCACCCAGCTGAAC
CGCGCCCTGACCGGCATCGCCGTGGAGCAGGACAAGAACACCCAGGAGGTGTTCGCCCAG
GTGAAGCAGATCTACAAGACCCCCCCCATCAAGGACTTCGGCGGCTTCAACTTCAGCCAG
ATCCTGCCCGACCCCAGCAAGCCCAGCAAGCGCAGCTTCATCGAGGACCTGCTGTTCAAC
AAGGTGACCCTGGCCGACGCCGGCTTCATCAAGCAGTACGGCGACTGCCTGGGCGACATC
GCCGCCCGCGACCTGATCTGCGCCCAGAAGTTCAACGGCCTGACCGTGCTGCCCCCCCTG
CTGACCGACGAGATGATCGCCCAGTACACCAGCGCCCTGCTGGCCGGCACCATCACCAGC
GGCTGGACCTTCGGCGCCGGCGCCGCCCTGCAGATCCCCTTCGCCATGCAGATGGCCTAC
CGCTTCAACGGCATCGGCGTGACCCAGAACGTGCTGTACGAGAACCAGAAGCTGATCGCC
AACCAGTTCAACAGCGCCATCGGCAAGATCCAGGACAGCCTGAGCAGCACCGCCAGCGCC
CTGGGCAAGCTGCAGGACGTGGTGAACCAGAACGCCCAGGCCCTGAACACCCTGGTGAAG
CAGCTGAGCAGCAACTTCGGCGCCATCAGCAGCGTGCTGAACGACATCCTGAGCCGCCTG
GACAAGGTGGAGGCCGAGGTGCAGATCGACCGCCTGATCACCGGCCGCCTGCAGAGCCTG
CAGACCTACGTGACCCAGCAGCTGATCCGCGCCGCCGAGATCCGCGCCAGCGCCAACCTG
GCCGCCACCAAGATGAGCGAGTGCGTGCTGGGCCAGAGCAAGCGCGTGGACTTCTGCGGC
AAGGGCTACCACCTGATGAGCTTCCCCCAGAGCGCCCCCCACGGCGTGGTGTTCCTGCAC
GTGACCTACGTGCCCGCCCAGGAGAAGAACTTCACCACCGCCCCCGCCATCTGCCACGAC
GGCAAGGCCCACTTCCCCCGCGAGGGCGTGTTCGTGAGCAACGGCACCCACTGGTTCGTG
ACCCAGCGCAACTTCTACGAGCCCCAGATCATCACCACCGACAACACCTTCGTGAGCGGC
AACTGCGACGTGGTGATCGGCATCGTGAACAACACCGTGTACGACCCCCTGCAGCCCGAG
CTGGACAGCTTCAAGGAGGAGCTGGACAAGTACTTCAAGAACCACACCAGCCCCGACGTG
GACCTGGGCGACATCAGCGGCATCAACGCCAGCGTGGTGAACATCCAGAAGGAGATCGAC
CGCCTGAACGAGGTGGCCAAGAACCTGAACGAGAGCCTGATCGACCTGCAGGAGCTGGGC
AAGTACGAGCAGTACATCAAGTGGCCCTGGTACATCTGGCTGGGCTTCATCGCCGGCCTG
ATCGCCATCGTGATGGTGACCATCATGCTGTGCTGCATGACCAGCTGCTGCAGCTGCCTG
AAGGGCTGCTGCAGCTGCGGCAGCTGCTGCTACCCCTACGACGTGCCCGACTACGCCTAA
ACCCAGCTTTCTTGTACAAAGTGGGCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCC
GAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGC
CGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTA
GGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAG
TTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGA
ACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTG
CAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAAT
GGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTA
TGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAA
AACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAAT
ATGGCCACAACCATGACCGAGTACAAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTC
CCCAGGGCCGTACGCACCCTCGCCGCCGCGTTCGCCGACTACCCCGCCACGCGCCACACC
GTCGATCCGGACCGCCACATCGAGCGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGC

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

29
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979

GTCGGGCTCGACATCGGCAAGGTGTGGGTCGCGGACGACGGCGCCGCGGTGGCGGTCTGG
ACCACGCCGGAGAGCGTCGAAGCGGGGGCGGTGTTCGCCGAGATCGGCCCGCGCATGGCC
GAGTTGAGCGGTTCCCGGCTGGCCGCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCAC
CGGCCCAAGGAGCCCGCGTGGTTCCTGGCCACCGTCGGCGTCTCGCCCGACCACCAGGGC
AAGGGTCTGGGCAGCGCCGTCGTGCTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTG
CCCGCCTTCCTGGAGACCTCCGCGCCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTC
ACCGTCACCGCCGACGTCGAGGTGCCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAG
CCCGGTGCCTGACAACTTTATTATACATAGTTGATCAATTCCGATAATCAACCTCTGGAT
TACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGT
GGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTC
TCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGG
CAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCC
ACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAA
CTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAAT
TCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCTCGCCTGTGTTGCCACC
TGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTT
CCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAG
ACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGGGAATTCCCGCGGTTCGCTTTA
AGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGA
CTGGAAGGGCTAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCT
CTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTT
AAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGAC
TCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTAGT
AGTTCATGTCATCTTATTATTCAGTATTTATAACTTGCAAAGAAATGAATATCAGAGAGT
GAGAGGAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAAT
TTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAAT
GTATCTTATCATGTCTGGCTCTAGCTATCCCGCCCCTAACTCCGCCCATCCCGCCCCTAA
CTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAG
AGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAG
GCCTAGGGACGTACCCAATTCGCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGT
CGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGC
ACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCA
ACAGTTGCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGC
GGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCC
TTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAA
TCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACT
TGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTT
GACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAA
CCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTT
AAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTAC
AATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAA
ATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATAT
TGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCG
GCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAA
GATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTT
GAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGT
GGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTAT
TCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATG
ACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTA
CTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGAT
CATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAG
CGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAA
CTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCA
GGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCC
GGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGT
ATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATC
GCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATAT
ATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTT
TTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGAC
CCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGC
TTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCA

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

30
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015

ACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTA
GTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT
CTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTG
GACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGC
ACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTA
TGAGAAAGCGCCACGCTTCCCGAAGAGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGG
GTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGT
CCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGG
CGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGG
CCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACC
GCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTG
AGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATT
CATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCA
ATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCT
CGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCAT
GATTACGCCAAGCGCGCAATTAACCCTCACTAAAGGGAACAAAAGCTGGAGCTGCAAGCT
T

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

31
1016
1017

1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030

Supplementary Figure 4. A) A combined transmembrane topology and signal peptide prediction
of ACE2 and TMPRSS2 as performed by Phobius (https://phobius.sbc.su.se). B) A topological
and subcellular localization prediction of ACE2 and TMPRSS2 as performed by Protter
(https://wlab.ethz.ch/protter/start/). Open-source tool for visualization of proteoforms and
interactive integration of annotated and predicted sequence features together with experimental
proteomic evidence.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.12.21253435; this version posted March 12, 2021. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

32
1031

Supplementary Figure 5.

1032

Sera

1033
1034
1035

25µL

1 2 3 4 5 6 7 8 9 10 11 12
1:2
1:4
1:8

1036

1:16

1037

1:64

1:32
1:128

1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071

1:256

Discard 25µL
1) Dilution of the sera
25µL of complete medium are added to each well of the microplate and 25 µL of each
serum is added to each well of the first line of wells. Than 25 µL of the first dilution of the
sera (1:2) are mixed and passed to the subsequent lines of wells. 25µL from the last line of
wells are discarded. Therefore, the final volume for each well is 25µL.
2) Adding the pseudovirus
4
25µL of pseudovirus in complete medium (corresponding to 10 RLUs; ~3-5µL of the
initial preparation) are added to each well and left at room temperature for 1,5 hours.
Final volume for each well is 50µL, therefore the sera dilution is doubled (1:4-1:8-1:161:32-1:64-1:128-1:256-1:512).
3) Adding the cells
4
50µL of complete medium containing 10 HEK/ACE2/TMPRRS2/Puro cells are added to
each well and left for 1,5 hours in cell incubator. Final volume for each well is 100µL.
4) Adding the Luciferine and reading
25µL of complete medium containing Luciferine (20µL of complete medium plus 5µL of
15mg/mL Luciferine in PBS) are added to each well just before the luminometric reading
of the microplate. Final volume for each well is 125µL. Since the plate has a transparent
bottom, a dark film layer should be applied for reading.
RLUs obtained were compared and normalized to those derived from wells where
pseudovirus were added in the absence of plasma/sera (100%). Neutralization titer 50
(NT50/mL) was expressed as the maximal dilution of the sera where the reduction of the
signal is ≥50%. This titer has to be multiplied per 40 because the initial volume of the sera
tested is 0,025mL and it has to be normalized to 1mL. This is a very important issue
because SN protocol could differ from each lab and the initial amount of sera tested could
be different in volume. However, in most of the case, operators tend to indicate SN50 and
not SN50/mL.

